<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934647</url>
  </required_header>
  <id_info>
    <org_study_id>8892-003</org_study_id>
    <secondary_id>2013-001680-23</secondary_id>
    <secondary_id>MK-8892-003</secondary_id>
    <nct_id>NCT01934647</nct_id>
  </id_info>
  <brief_title>Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)</brief_title>
  <official_title>A Non-randomized, Single-Panel, Open-Label Trial to Study the Safety, Tolerability and Pharmacodynamics of MK-8892 Acute Dosing in Subjects With Moderate to Severe Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will study the safety, tolerability, and pharmacodynamics of single doses
      of MK-8892 in participants with pulmonary arterial hypertension (PAH). The primary objective
      is to estimate the measured peak effect of the highest acutely tolerated (HAT) single oral
      dose of MK-8892 on pulmonary vascular resistance (PVR).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">November 22, 2013</start_date>
  <completion_date type="Actual">September 8, 2014</completion_date>
  <primary_completion_date type="Actual">September 8, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at the Highest Acutely Tolerated (HAT) Dose of MK-8892</measure>
    <time_frame>Baseline and up to 5 hours post-dose</time_frame>
    <description>PVR assessments were performed throughout the right heart catheterization (RHC). Peak PVR reduction was determined to occur if 2 consecutive PVR measurements were at least 20% greater than the nadir PVR measurement.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>1 mg MK-8892</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of 1 mg MK-8892.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg MK-8892</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of 4 mg MK-8892.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg MK-8892</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of 8 mg MK-8892.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8892</intervention_name>
    <description>Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892</description>
    <arm_group_label>1 mg MK-8892</arm_group_label>
    <arm_group_label>4 mg MK-8892</arm_group_label>
    <arm_group_label>8 mg MK-8892</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postmenopausal female or if female of reproductive potential, remains abstinent or
             uses two acceptable methods of birth control during 14 days after dosing with MK-8892

          -  has suspected PAH classified in one of the following sub-groups: idiopathic,
             heritable, drug- or toxin-induced, or associated with connective tissue disease, as
             defined by the Dana Point 2008 Clinical Classification

          -  has a clinical indication for right heart catheterization

          -  PAH classified as World Health Organization (WHO) functional class II or III

        Exclusion Criteria:

          -  has a medical history indicating a secondary cause of Pulmonary Hypertension (PH) or a
             non-included etiology of PAH including the following tests within 6 months of Visit 1:
             Echo indicating significant left heart disease, valvular disease, or structural
             defects; function test indicating significant pulmonary disease; imaging test
             indicating veno-occlusive disease; perfusion scan indicating thromboembolic disease;
             abdominal ultrasound indicating cirrhosis; positive test for human immunodeficiency
             virus (HIV)

          -  has persistent or permanent atrial fibrillation, significantly impaired gas exchange,
             history of radiation of the lung or mediastinum, hepatic or hepatobiliary disease,
             immunodeficiencies or latent bleeding risk

          -  has estimated Glomerular Filtration Rate (GFR) &lt;45 mL/min

          -  has alanine aminotransferase test (ALT) serum glutamic pyruvic transaminase (SGPT) or
             aspartate aminotransferase test (AST) serum glutamic oxaloacetic transaminase (SGOT)
             &gt;= 3 x upper limit of normal (ULN) at Visit 1

          -  has a systolic blood pressure (BP) &lt;105 mmHg, or heart rate (HR) &gt; 100 beats/min at
             Visit 1 (Day -7 to -1)

          -  has previously received specific therapy for PAH within 4 weeks prior to Visit 1

          -  has taken sildenafil, valdenafil or a nitrate within 24 hours prior to Visit 2 date

          -  has taken tadalafil within 7 days prior to Visit 2 date

          -  has taken 2 or more specific PAH medications concomitantly within 4 weeks of
             anticipated Visit 2 date. Only treatment na√Øve subjects or subjects on stable
             PAH-specific monotherapy with an endothelin receptor antagonist ([ERA]; bosentan,
             ambrisentan, or macitentan) or a prostacyclin analog ([PCA]; treprostinil,
             epoprostenol, or iloprost) are eligible. PAH monotherapy with one of these medications
             may continue without interruption during this study

          -  has taken a soluble guanylate cyclase (sGC) activator (riociguat) within 24 hours of
             anticipated Visit 2 date.

          -  has taken diltiazem immediate release within 1 day or diltiazem extended release
             within 2 days prior to Visit 2 date

          -  is currently taking potent inhibitors or inducers of Cytochrome P450 3A4 (CYPA4), or
             is consuming &gt;1 liter of grapefruit juice per day

          -  is pregnant or breastfeeding or expecting to conceive during study or post study
             follow-up period

          -  has donated 500 mL of blood within prior 60 days

          -  is currently participating in or has within the prior three months participated in a
             study with an investigational compound or device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <results_first_submitted>March 12, 2018</results_first_submitted>
  <results_first_submitted_qc>March 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2018</results_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 mg MK-8892</title>
          <description>Participants received a single oral dose of 1 mg MK-8892.</description>
        </group>
        <group group_id="P2">
          <title>4 mg MK-8892</title>
          <description>Participants received a single oral dose of 4 mg MK-8892.</description>
        </group>
        <group group_id="P3">
          <title>8 mg MK-8892</title>
          <description>Participants received a single oral dose of 8 mg MK-8892.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 mg MK-8892</title>
          <description>Participants received a single oral dose of 1 mg MK-8892.</description>
        </group>
        <group group_id="B2">
          <title>4 mg MK-8892</title>
          <description>Participants received a single oral dose of 4 mg MK-8892.</description>
        </group>
        <group group_id="B3">
          <title>8 mg MK-8892</title>
          <description>Participants received a single oral dose of 8 mg MK-8892.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="17.7"/>
                    <measurement group_id="B2" value="52.0" spread="1.4"/>
                    <measurement group_id="B3" value="61.3" spread="11.0"/>
                    <measurement group_id="B4" value="51" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at the Highest Acutely Tolerated (HAT) Dose of MK-8892</title>
        <description>PVR assessments were performed throughout the right heart catheterization (RHC). Peak PVR reduction was determined to occur if 2 consecutive PVR measurements were at least 20% greater than the nadir PVR measurement.</description>
        <time_frame>Baseline and up to 5 hours post-dose</time_frame>
        <population>Planned efficacy analysis could not be performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg MK-8892</title>
            <description>Participants received a single oral dose of 1 mg MK-8892.</description>
          </group>
          <group group_id="O2">
            <title>4 mg MK-8892</title>
            <description>Participants received a single oral dose of 4 mg MK-8892.</description>
          </group>
          <group group_id="O3">
            <title>8 mg MK-8892</title>
            <description>Participants received a single oral dose of 8 mg MK-8892.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at the Highest Acutely Tolerated (HAT) Dose of MK-8892</title>
          <description>PVR assessments were performed throughout the right heart catheterization (RHC). Peak PVR reduction was determined to occur if 2 consecutive PVR measurements were at least 20% greater than the nadir PVR measurement.</description>
          <population>Planned efficacy analysis could not be performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after study drug administration</time_frame>
      <desc>Safety analysis included all participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panel A: 1 mg</title>
          <description>Participants received a single oral dose of 1 mg MK-8892.</description>
        </group>
        <group group_id="E2">
          <title>Panel B: 4 mg</title>
          <description>Participants received a single oral dose of 4 mg MK-8892.</description>
        </group>
        <group group_id="E3">
          <title>Panel C: 8 mg</title>
          <description>Participants received a single oral dose of 8 mg MK-8892.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

